Rare Metabolic Disorders
Sanofi Winthrop Industrie supports clinical research in glycogen storage disease type II, with attention to Pompe disease and long-term patient follow-up in France.
- Avalglucosidase alfa
- Post-trial access
- Long-term safety
The sponsor’s activity in this area is centered on ongoing care pathways for patients who have completed earlier treatment studies.
Lysosomal Storage Diseases
Clinical research also focuses on Niemann-Pick disease, particularly acid sphingomyelinase deficiency and its management across pediatric and adult populations.
- Olipudase alfa
- Safety and tolerability
- Acid sphingomyelinase deficiency (ASMD)
These studies reflect an interest in treatment continuity for patients transitioning beyond prior clinical trial participation.
Patient Follow-up in France
The sponsor’s trials are concentrated in France, with research activity linked to continued observation of patients after earlier study completion.
- Clinical follow-up
- Reimbursement-linked access
- Specialist site collaboration
This area includes research conducted through multiple collaborating sites within the French clinical network.
Pediatric and Adult Rare Disease Care
Sanofi Winthrop Industrie is involved in rare disease studies spanning both pediatric and adult participants, with emphasis on chronic disease monitoring and treatment access.
- Chronic safety assessment
- Therapeutic continuity
- Rare disease populations
Its research portfolio highlights sustained clinical interest in enzyme replacement therapies for inherited metabolic conditions.
